Match tier Likely match
Presence Current · Arkansas
Last published 2025
Sources OpenAlex · ORCID
Refreshed 2026-08-16

Àlex Soriano

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Jefe de Servicio

Faculty Researcher

79 h-index 699 pubs 26,088 cited

  • Humans
  • Male
  • Female
  • Aged
  • Middle Aged
  • Anti-Bacterial Agents
  • Prosthesis-Related Infections
  • Adult
  • Retrospective Studies
  • Aged, 80 and over
  • Treatment Outcome
  • Bacteremia
  • COVID-19
  • Prospective Studies
  • Staphylococcal Infections

Biography and Research Information

OverviewAI-generated summary

Àlex Soriano's research focuses on infectious diseases, antimicrobial resistance, and treatment strategies, particularly within adult populations. His work includes investigating novel antifungal agents, as demonstrated by his participation in the ReSTORE trial evaluating rezafungin versus caspofungin for candidemia and invasive candidiasis. He has also contributed to understanding the challenges and unmet needs in managing invasive candidiasis.

Soriano's research extends to bacterial infections, including a systematic review on the nephrotoxicity and neurotoxicity associated with polymyxin use and an observational study on the role of rifampin in staphylococcal periprosthetic joint infections. He has also been involved in guideline development for septic arthritis and has examined the immune response to SARS-CoV-2 vaccination in transplant recipients and the impact of SARS-CoV-2 infection in adults living with HIV. With a substantial publication record and high citation counts, Soriano's work contributes to the clinical management and understanding of complex infectious diseases.

Metrics

  • h-index: 79
  • Publications: 699
  • Citations: 26,088

Selected Publications

  • Debridement, antimicrobial therapy, and implant retention (DAIR) as curative strategy for acute periprosthetic hip and knee infections: a position paper of the European Bone & Joint Infection Society (EBJIS) (2025)
    18 citations DOI OpenAlex
  • Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study (2025)
    19 citations DOI OpenAlex
  • Prevalence and impact of multidrug-resistant bacteria in solid cancer patients with bloodstream infection: a 25-year trend analysis (2024)
    Microbiology Spectrum 29 citations DOI OpenAlex
  • Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018–2022 (2024)
    Journal of Global Antimicrobial Resistance 101 citations DOI OpenAlex
  • Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial (2024)
    The Lancet Infectious Diseases 88 citations DOI OpenAlex
  • Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials (2023)
    The Lancet Infectious Diseases 79 citations DOI OpenAlex
  • Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial (2023)
    Nature Medicine 45 citations DOI OpenAlex
  • A second update on mapping the human genetic architecture of COVID-19 (2023)
    Nature 118 citations DOI OpenAlex
  • Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel (2023)
    International Journal of Antimicrobial Agents 55 citations DOI OpenAlex
  • Carbapenem-Resistant <i>Acinetobacter</i> spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic (2023)
    Open Forum Infectious Diseases 32 citations DOI OpenAlex
  • High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations (2023)
    22 citations DOI OpenAlex
  • Invasive candidiasis: current clinical challenges and unmet needs in adult populations (2023)
    Journal of Antimicrobial Chemotherapy 181 citations DOI OpenAlex
  • Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study (2023)
    Journal of Infection 70 citations DOI OpenAlex
  • Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial (2023)
    The Lancet Regional Health - Europe 32 citations DOI OpenAlex
  • Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series (2023)
    22 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

561 Collaborators 267 Institutions 37 Countries

Top Collaborators

Similar Researchers

Based on overlapping research topics